Drug Profile
Omarigliptin - Merck
Alternative Names: Marizev; MK-3102Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Class 2 ring heterocyclic compounds; Antihyperglycaemics; Fluorobenzenes; Pyrazoles; Pyrrolidines; Small molecules; Sulfonamides
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 06 Apr 2017 Merck terminates a phase III trial for Type-2 diabetes mellitus due to business reasons in USA, Austria, Belgium, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Lithuania, the Netherlands, Norway, Slovakia, Poland, Spain and Sweden (NCT01703208)
- 20 Feb 2017 Merck re-initiates enrolment in a phase III trial for Type-2 diabetes mellitus in USA, Austria, Belgium, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Lithuania, the Netherlands, Norway, Slovakia, Poland, Spain and Sweden (NCT01703208)
- 31 May 2016 Merck terminates a phase III trial for Type-2 diabetes mellitus in USA, Austria, Belgium, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Lithuania, the Netherlands, Poland, Spain and Sweden due to business reasons (NCT01703208)